MedTrace Logo

Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema

NCT00571142 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-05-31

No results posted yet for this study

Summary

To Evaluate combined effect of vitrectomy and bevacizumab to stabilize retinal thickness and visual acuity in patients with diffuse diabetic macular edema and their relation to renal disease.

Conditions

  • Diffuse Diabetic Macular Edema

Interventions

PROCEDURE

Bevacizumab + Pars plana vitrectomy

2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional.

PROCEDURE

Bevacizumab + pars plana vitrectomy

2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy

Sponsors & Collaborators

  • Asociación para Evitar la Ceguera en México

    lead OTHER

Principal Investigators

  • Veronica Kon-Jara, MD · Asociación para Evitar la Ceguera en México

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2007-11-30
Completion
2008-02-29

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00571142 on ClinicalTrials.gov